Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 723 JPY 7.59% Market Closed
Market Cap: 10.6B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Perseus Proteomics Inc
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Capital Expenditures
-ÂĄ159m
CAGR 3-Years
-283%
CAGR 5-Years
-60%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Capital Expenditures
-ÂĄ1.8B
CAGR 3-Years
-71%
CAGR 5-Years
-20%
CAGR 10-Years
-24%
PeptiDream Inc
TSE:4587
Capital Expenditures
-ÂĄ2B
CAGR 3-Years
-18%
CAGR 5-Years
-60%
CAGR 10-Years
-36%
Takara Bio Inc
TSE:4974
Capital Expenditures
-ÂĄ12.2B
CAGR 3-Years
-6%
CAGR 5-Years
-17%
CAGR 10-Years
-10%
Pharma Foods International Co Ltd
TSE:2929
Capital Expenditures
-ÂĄ973m
CAGR 3-Years
-78%
CAGR 5-Years
-28%
CAGR 10-Years
-55%
C
Cuorips Inc
TSE:4894
Capital Expenditures
-ÂĄ35.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
10.3B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
719.16 JPY
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Capital Expenditures?
Capital Expenditures
-159m JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Capital Expenditures amounts to -159m JPY.

What is Perseus Proteomics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-60%

Over the last year, the Capital Expenditures growth was 7%. The average annual Capital Expenditures growth rates for Perseus Proteomics Inc have been -283% over the past three years , -60% over the past five years .

Back to Top